Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. (Nasdaq: NXL) is a medical device company that develops non-invasive, frequency-based neurostimulation products aimed at mental health and neurological conditions. The Nexalin news feed on Stock Titan highlights company announcements, clinical study results, regulatory milestones, and capital markets updates related to its Deep Intracranial Frequency Stimulation (DIFS™) technology.
Recent news releases describe peer-reviewed studies in Alzheimer’s disease, dementia, Attention Deficit Hyperactivity Disorder (ADHD), and a case involving gambling disorder with alcohol use disorder, where Nexalin’s 15 milliamp DIFS™ devices were associated with cognitive improvements, changes in brain network activity, and favorable safety profiles. Other updates cover regulatory approvals for the Gen-2 SYNC console in markets such as Israel, China, Brazil, and Oman, as well as U.S. FDA Q-Submission interactions for Alzheimer’s and dementia programs.
Investors and observers can use this page to follow Nexalin’s progress in advancing its Gen-2 and Gen-3 platforms, including the Gen-2 SYNC console and the Gen-3 HALO™ Clarity headset, along with developments in areas like traumatic brain injury research and international distribution agreements. News items also include information on investor events, such as webinars and conference participation, and SEC-related disclosures that may influence the company’s strategic and financial position.
By reviewing the NXL news stream, readers gain insight into how Nexalin’s DIFS™ technology is being evaluated in clinical settings, how regulators are engaging with its devices, and how the company is positioning its non-invasive, drug-free neuromodulation platform within the broader mental health and neurodegenerative disease landscape.
Nexalin Technology (Nasdaq: NXL) announced three independently peer‑reviewed studies (Alzheimer's Research & Therapy; Journal of Alzheimer’s Disease; Radiology) showing cognitive and network benefits from its 15 mA Gen‑2 Deep Intracranial Frequency Stimulation (DIFS) device.
Key study details: a randomized double‑blind trial (46 patients) used 30 one‑hour DIFS sessions over 15 days with immediate MMSE and MoCA gains; fMRI studies reported increased hippocampal activation, fALFF, ReHo and improved hippocampus–cortex connectivity. The company frames DIFS as a non‑invasive, drug‑free alternative with no reported serious side effects.
Nexalin Technology (Nasdaq: NXL) appointed Dr. Robert Rothstein to its Scientific Advisory Board to support Alzheimer’s disease and traumatic brain injury (TBI) programs and to aid preparation of a Q-submission with the FDA later in 2025. Dr. Rothstein brings 40+ years of clinical and translational experience in emergency medicine, psychiatric care, and medical technology advisory roles.
Nexalin plans to initiate Alzheimer’s-specific trials in Q4 2025 and targets a TBI-focused submission thereafter, leveraging MEG-guided protocols, imaging biomarkers, and expanded SAB oversight.
Nexalin Technology (Nasdaq: NXL, NXLIW) announced it will participate in the 2025 Maxim Growth Summit on October 22, 2025 at The Hard Rock Hotel NYC.
Management will meet attendees to discuss Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™), described as a non-invasive, drug-free, clinically proven neurostimulation therapy the company says has potential to scale worldwide.
The announcement highlights investor and public engagement opportunities at the conference and provides registration details for the Maxim Growth Summit.
Nexalin Technology (Nasdaq: NXL) reported peer-reviewed clinical results (Radiology, Oct 8, 2025) showing its Gen-2 SYNC 40-Hz, 15 mA DIFS neurostimulation device produced statistically significant cognitive gains and measurable brain-connectivity changes in mild Alzheimer’s disease.
Key findings: significant MMSE and MoCA score improvements versus sham (P = .001 and .03), increased hippocampal-cortical and network functional connectivity on resting-state fMRI, a connectivity–naming-test correlation (r = 0.65, FDR-adjusted P = .008), and no reported adverse events. Device has regulatory approvals for other indications in China, Brazil, and Oman.
Nexalin Technology (NASDAQ: NXL) has secured U.S. Design Patent No. D1,092,758 for its HALO™ Clarity neuromodulation device, providing 15 years of design protection. The device utilizes the company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology to deliver non-invasive, drug-free treatment for mental health and neurological conditions.
The HALO™ Clarity system enables at-home, professionally supervised treatment with remote monitoring capabilities. The company is conducting multiple clinical studies across various indications including anxiety, insomnia, PTSD, and mild traumatic brain injury. The FDA has already provided consensus on pivotal trial designs for anxiety and insomnia indications.
The DIFS™ platform has demonstrated safety and efficacy signals in over two dozen trials worldwide. Nexalin has completed usability, safety, and design verification testing and is scaling manufacturing for broader clinical deployment.
Nexalin Technology (NASDAQ: NXL) will host a live investor webinar on September 9, 2025, at 4:15 p.m. ET. CEO Mark White will present the company's Deep Intracranial Frequency Stimulation (DIFS™) technology and its applications in mental healthcare.
The presentation will highlight clinical collaborations with institutions like UC San Diego, updates on the Gen-3 HALO™ Clarity headset, and the Virtual Clinic model for at-home treatment. Operating in a $537 billion mental health market, Nexalin's strategy includes international regulatory approvals, U.S. market expansion, and AI-driven patient monitoring.
Nexalin Technology (NASDAQ: NXL), a leader in Deep Intracranial Frequency Stimulation (DIFS™), has appointed Justin Van Fleet, CPA as Chief Financial Officer effective August 1, 2025. Van Fleet brings over 20 years of experience in public accounting and assurance services, most recently as Partner at Marcum LLP.
The appointment comes at a crucial time as Nexalin advances its Generation 2 and Generation 3 devices through FDA review. These non-invasive neurostimulation systems are designed to treat anxiety, depression, and other mental health conditions without drugs or surgery. Van Fleet will oversee the company's financial strategy, planning, and reporting functions during this critical growth phase.
Nexalin Technology (Nasdaq: NXL) will host a live investor webinar on June 3, 2025, at 4:15 p.m. ET. CEO Mark White will present the company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology for mental healthcare and provide updates on their Gen-3 HALO™ Clarity headset and Virtual Clinic model for at-home treatment. The presentation will highlight clinical collaborations with institutions like UC San Diego, international regulatory approvals, and U.S. expansion plans in the $537 billion mental health market. The webinar will include discussion of Nexalin's patented technology, AI-driven patient monitoring, and global expansion strategy, followed by a Q&A session.
Nexalin Technology (NASDAQ: NXL) has reconstituted its Scientific Advisory Board (SAB) with three leading experts to advance its Alzheimer's disease program. The company appointed Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer to guide its clinical development of Deep Intracranial Frequency Stimulation (DIFS™) technology.
Nexalin's Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform technology that can penetrate deep brain structures. Recent data suggests DIFS™ may promote neuroplasticity and functional recovery in memory and executive function regions. The company plans to initiate new Alzheimer's-focused clinical studies in Q3 2025, incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics.
Nexalin Technology (NASDAQ: NXL), a company specializing in Deep Intracranial Frequency Stimulation (DIFS™) technology, has successfully closed its previously announced underwritten public offering. The company issued 3,850,000 shares of common stock at $1.30 per share, raising approximately $5.0 million in gross proceeds before deducting underwriting costs and other expenses.
The offering was conducted through Maxim Group LLC as the sole book-running manager, under an effective shelf registration statement on Form S-3. The securities were offered through a prospectus and prospectus supplement, with documentation available on the SEC's website.